Study #2022-0751
An Open-label phase 1b study of E7386 in combination with other Anticancer Drug(s) in subjects with solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
E7386, Lenvatinib
Description
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms
Study phase:
Phase I
Physician name:
Kanwal Raghav
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.